19 K-biosimilar products sold in 11 markets after 12 yrs
By Chon, Seung-Hyun | translator Kim, Jung-Ju
24.04.25 06:18:10
가나다라
0
3 Samsung Bioepis biosimilars were approved in Korea this year
Celltrion’s Remsima was first approved in 2012... Remicade, Stelara approved in 11 regions
Samsung Bioepis owns 9 products, the most amount of licensed biosimilar products…Cetllrion commercialized 6 products
Domestic pharmaceutical and biotech companies have succeeded in commercializing biosimilars in 11 areas. In the 12 years since Celltrion's Remsima was introduced, 19 biosimilars have received domestic approval. Among the companies, Samsung Bioepis has entered 9 markets, the most among Korean companies.
According to the Ministry of Food and Drug Safety, Samsung Bioepis received approval for Stelara’s biosimilar Epyztek on November 11. This is the first time Samsung Bioepis has received approval for a Stelara biosimilar in Korea.
Stelara, which was developed by Janssen, inhibits the activity of interleukin (IL)-12/23, a type of inflammatory cytokine related to autoimmune diseases, and is use
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)